ValiRx Plc
("ValiRx" or "the Company")
"VALIRX ESTABLISHES US OFFICE IN BOSTON, MASSACHUSETTS & STRENGTHENS ITS US ADVISORY TEAM"
London, UK, 5th November 2015: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that it has established US operations in Cambridge, Boston, Massachusetts and has strengthened its US advisory team following the appointment of industry specific advisors in the US.
The US operation is being formed to encourage and facilitate greater interaction with academic, clinical and business leaders in ValiRx's areas of oncological development. Our new office in Kendall Square, Cambridge, close by the Massachusetts Institute of Technology ("MIT") will be advantageous to the business as we look to expand our co-operation with biotech and pharma players in the US market.
Dr Satu Vainikka, CEO of ValiRx, commented: "ValiRx's expansion into the US is part of our strategy to strengthen our investor base and to take advantage of close proximity to the biggest biotech market in the World. With VAL201 progressing in the Phase I/II trial and VAL401 on the verge of entering a Phase IIb Clinical Trial, we also felt it important to support our drug development programme by strengthening the team, particularly in the US. It is an exciting time for the group and I look forward to benefiting rapidly from our US presence."
*** ENDS ***
For more information, please contact:
ValiRx plc |
Tel: +44 (0) 20 3008 4416 |
Dr Satu Vainikka |
www.valirx.com |
|
|
Cairn Financial Advisers LLP (Nominated Adviser) |
Tel: +44 (0) 20 7148 7900 |
Liam Murray / Avi Robinson |
|
|
|
Northland Capital Partners Limited (Broker) |
Tel: +44 (0) 20 7382 1100 |
Patrick Claridge / David Hignell (Corporate Finance) John Howes / Abigail Wayne (Broking) |
|
Peckwater PR |
Tel: +44 (0) 7879 458 364 |
Tarquin Edwards |
[email protected] |
Notes for Editors
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006.
The Company has a pipeline of other therapeutic drugs, which are currently progressing towards clinical trials. The product focus is in the targeted analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases. It actively manages projects within its portfolio as a trading company. The ValiRx business model spreads the risks of life science technology development by minimizing financial exposure and running a set of projects to defined commercial endpoints. This maximizes returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.
The Company operates through the following divisional companies:
1. ValiPharma is the therapeutics division, with two embedded technologies primarily directed at the treatment of cancers.
2. ValiFinn is the biomarkers and diagnostic development division. ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technology later in the year to strengthen the portfolio.
3. ValiSeek is a joint venture between ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentially other indications.
